Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial

Breast Cancer Research and Treatment

Volumn 148, Issue 1, 2014, Pages 81-90

  DeCensi, Andrea ^a   Puntoni, Matteo ^a   Gandini, Sara ^b   Guerrieri Gonzaga, Aliana ^b   Johansson, Harriet Ann ^b   Cazzaniga, Massimiliano ^b   Pruneri, Giancarlo ^b,c   Serrano, Davide ^b   Schwab, Matthias ^d,e   Hofmann, Ute ^d,f   Mora, Serena ^b   Aristarco, Valentina ^b   Macis, Debora ^b   Bassi, Fabio ^b   Luini, Alberto ^b   Lazzeroni, Matteo ^b   Bonanni, Bernardo ^b   Pollak, Michael N ^g  

^a GALLIERA HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

Breast cancer; Clinical trial; HER2 breast cancer; Insulin resistance; ki 67; Metformin

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; METFORMIN; PLACEBO; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; ANTIDIABETIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER CLASSIFICATION; CANCER SURGERY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ADULT; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECTS; PATHOLOGY;

ADULT; BREAST NEOPLASMS; CELL PROLIFERATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METFORMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84922005443     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3141-1     Document Type: Article

References (51)

1. Pollak M (2013) Potential applications for biguanides in oncology. J Clin Invest 123:3693–3700
2. Goodwin PJ, Ligibel JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27:3271–3273
3. Pollak M (2014) Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 20:591–593
4. Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7:867–885
5. Lega IC, Austin PC, Gruneir A et al (2013) Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36:3018–3026
6. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
7. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2:778–790
8. He X, Esteva FJ, Ensor J et al (2012) Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2 + breast cancer. Ann Oncol 23:1771–1780
9. Bonanni B, Puntoni M, Cazzaniga M et al (2012) Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. J Clin Oncol 30:2593–2600
10. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
11. Hadad S, Iwamoto T, Jordan L et al (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128:783–794
12. Niraula S, Dowling RJ, Ennis M et al (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135:821–830
13. Cazzaniga M, Decensi A, Pruneri G et al (2013) The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109:2792–2797
14. Kalinsky K, Crew KD, Refice S et al (2014) Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer. Cancer Invest 32:150–157
15. (GENERIC)Ref Type: Electronic Citation 2014.http://www.drugs.com/pro/metformin.html.
16. http://www.agenziafarmaco.gov.it/it/content/recommendations on the use of metformin (2011).08/04/201
17. Jones GC, Macklin JP, Alexander WD (2003) Contraindications to the use of metformin. BMJ 326:4–5
18. Viale G, Giobbie-Hurder A, Regan MM et al (2008) Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26:5569–5575
19. Dowsett M, Nielsen TO, A’Hern R et al (2011) Assessment of Ki67 in Breast Cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664
20. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747
21. Johansson H, Gandini S, Guerrieri-Gonzaga A et al (2008) Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 68:9512–9518
22. Fendt SM, Bell EL, Keibler MA et al (2013) Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 73:4429–4438
23. Senn S (1994) Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 13:197–198
24. Bonetti M, Gelber RD (2004) Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 5:465–481
25. Gandini S, Guerrieri-Gonzaga A, Pruneri G et al (2013) Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. Ann Oncol 25:618–623
26. Goodwin PJ, Parulekar W, Gelmon KA et al (2013). Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). J Clin Oncol 31 (suppl; abstr 1033)
27. Decensi A, Robertson C, Viale G et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779–790
28. Decensi A, Puntoni M, Pruneri G et al (2011) Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) 4:1181–1189
29. Tagliabue E, Agresti R, Carcangiu ML et al (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362:527–533
30. Spigel DR (2003) HER2 and surgery: more questions to answer. Lancet 362:502–503
31. Zhu P, Davis M, Blackwelder AJ et al (2014) Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) 7:199–210
32. Martin-Castillo B, Dorca J, Vazquez-Martin A et al (2010) Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann Oncol 21:187–189
33. Phoenix KN, Vumbaca F, Fox MM et al (2010) Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res Treat 123:333–344
34. Algire C, Amrein L, Bazile M et al (2011) Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30:1174–1182
35. Jeon SM, Chandel NS, Hay N (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485:661–665
36. Goodwin PJ, Ennis M, Pritchard KI et al (2012) Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. J Clin Oncol 30:164–171
37. Pritchard KI, Shepherd LE, Chapman JA et al (2011) Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 29:3869–3876
38. Wolpin BM, Meyerhardt JA, Chan AT et al (2009) Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176–185
39. Ma J, Li H, Giovannucci E et al (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9:1039–1047
40. Belfiore A, Frasca F, Pandini G et al (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586–623
41. Law JH, Habibi G, Hu K et al (2008) Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68:10238–10246
42. Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18:R125–R147
43. Carstensen B, Witte DR, Friis S (2012) Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia 55:948–958
44. Leow MK (2012) Basal insulin and cardiovascular and other outcomes. N Engl J Med 367:1763–1764
45. Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20:42–51
46. Doogue MP, Begg EJ, Moore MP et al (2009) Metformin increases plasma ghrelin in Type 2 diabetes. Br J Clin Pharmacol 68:875–882
47. Robert F, Fendri S, Hary L, Lacroix C et al (2003) Kinetics ofplasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab 29:279–283
48. Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98
49. Musi N, Hirshman MF, Nygren J et al (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074–2081
50. Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol 29:2342–2348
51. Martin-Montalvo A, Mercken EM, Mitchell SJ et al (2013) Metformin improves healthspan and lifespan in mice. Nat Commun 4:2192